Expectations trend
FY2027 · fiscal year ending 2027-12-28 · fmp
Kenvue (KVUE)
NYSEConsumer StaplesHousehold & Personal ProductsSnapshot 2026-11-05
$19.31-1.28%
Close 2026-10-30 · 1-day change
NYSEConsumer StaplesHousehold & Personal ProductsSnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
1.25 → 1.24 EPS · FY ending Dec 28, 2027 · 7 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 6, 2026 to Nov 5, 2026: (new ÷ prior − 1). Contributor count changed from 8 to 7; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for KVUE yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
5 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Smooth CFO transition maintaining financial stability | A supporting condition in Kenvue's published investment case. The stated target is No major financial disruptions or guidance cuts due to CFO change. | Under Pressure | significant financial instability or guidance cuts linked to CFO transition | Q3 profit miss vs no guidance cuts target Kenvue missed third-quarter profit expectations; merger closed with debt funding. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-28 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
KVUE is a consumer staples business with a relatively low-risk profile and a sector backdrop described as a tailwind. Its long-term thesis is intact, supported by recent financial performance, though management execution is mixed and the Kimberly-Clark combination remains pending.
Valuation is neutral, with KVUE at roughly peer-level valuation and expectations broadly aligned with the evidence. The priced-in assessment is tagged unjustified, but fragility is low, so the snapshot does not point to a concentrated expectations risk.
Near term, recent results show four consecutive quarters of net and organic sales growth, with the latest quarter reporting 3.2% net sales growth and 2.9% organic sales growth year over year. Margins improved in part through supply-chain productivity and cost optimization, though the contribution is not quantified; guidance cuts and a weakening jobs report are risks, despite the low estimated miss probability.
The multi-year view depends partly on whether management completes the pending Kimberly-Clark combination, which has shown limited substantive progress in the latest quarter. Near term, continued sales growth and operating efficiency would support the thesis, while a guidance cut could weaken it; stronger results and guidance from sector peers could support the broader staples backdrop.
Over the next 1 to 3 years, KVUE’s long-term thesis is intact, with recent growth and margin progress balanced against uncertain transaction delivery and guidance risk. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Profit margins remain stable with EPS around $1.02 for 2025. |
| Intact |
| EPS falls below $1.00 for 2025 |
Diluted EPS: $0.22 per share FY2026-Q3; GAAP. Published target: ~$1.02 EPS for 2025. Target period ends 2025-12-31; this observation covers 2026-Q3. Oct 30, 20260.22 USD/share · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Net sales growth near 4.5% YoY | A primary condition in Kenvue's published investment case. The stated target is >=4.5% YoY net sales growth. | Broken | net sales growth falls below 3% YoY | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Progress on 2026 restructuring initiative | A supporting condition in Kenvue's published investment case. The stated target is Progress score >= 40%. | Intact | progress score falls below 30% by end 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Organic sales growth at or above 0.7% quarterly | Kenvue grows sales about 4.5% yearly, driven by organic growth and market expansion. | Intact | organic sales growth falls below 0.7% quarterly | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$1.26 → $1.24 · observed estimates
$16.02B → $15.98B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $1.26 | $16,017,673,671 | 9 / 10 |
| 2026-07-25 | $1.26 | $16,017,673,671 | 9 / 10 |
| 2026-07-26 | $1.26 | $16,017,673,671 | 9 / 10 |
| 2026-07-27 | $1.26 | $16,017,673,671 | 9 / 10 |
| 2026-07-28 | $1.26 | $16,017,673,672 | 9 / 10 |
| 2026-07-29 | $1.26 | $16,017,673,672 | 9 / 10 |
| 2026-07-30 | $1.26 | $16,017,673,672 | 9 / 10 |
| 2026-07-31 | $1.26 | $16,017,673,672 | 9 / 10 |
| 2026-08-01 | $1.26 | $16,017,673,672 | 9 / 10 |
| 2026-08-02 | $1.26 | $16,017,673,672 | 9 / 10 |
| 2026-08-03 | $1.26 | $16,017,673,672 | 9 / 10 |
| 2026-08-04 | $1.26 | $16,017,673,672 | 9 / 10 |
| 2026-08-05 | $1.26 | $16,017,673,672 | 9 / 10 |
| 2026-08-06 | $1.26 | $16,017,673,672 | 9 / 10 |
| 2026-08-07 | $1.26 | $16,017,673,672 | 8 / 10 |
| 2026-08-08 | $1.26 | $16,017,673,672 | 8 / 10 |
| 2026-08-09 | $1.26 | $16,017,673,672 | 8 / 10 |
| 2026-08-10 | $1.26 | $16,017,673,672 | 8 / 10 |
| 2026-08-12 | $1.26 | $16,017,673,672 | 8 / 10 |
| 2026-08-13 | $1.26 | $16,017,673,672 | 8 / 10 |
| 2026-08-14 | $1.26 | $16,017,673,672 | 8 / 10 |
| 2026-08-15 | $1.26 | $16,017,673,672 | 8 / 10 |
| 2026-08-16 | $1.26 | $16,017,673,672 | 8 / 10 |
| 2026-08-17 | $1.26 | $16,017,673,672 | 8 / 10 |
| 2026-08-18 | $1.26 | $16,017,673,672 | 8 / 10 |
| 2026-08-19 | $1.26 | $16,017,673,672 | 8 / 10 |
| 2026-08-20 | $1.24 | $15,962,072,866 | 8 / 10 |
| 2026-08-21 | $1.24 | $15,962,072,866 | 8 / 10 |
| 2026-08-22 | $1.24 | $15,961,345,593 | 8 / 10 |
| 2026-08-23 | $1.24 | $15,961,345,593 | 8 / 10 |
| 2026-08-24 | $1.24 | $15,961,345,593 | 8 / 10 |
| 2026-08-25 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-08-26 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-08-27 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-08-28 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-08-29 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-08-30 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-08-31 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-09-01 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-09-02 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-09-03 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-09-04 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-09-05 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-09-06 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-09-07 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-09-08 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-09-09 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-09-10 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-09-11 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-09-12 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-09-13 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-09-14 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-09-15 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-09-16 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-09-17 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-09-18 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-09-19 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-09-20 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-09-21 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-09-22 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-09-23 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-09-24 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-09-25 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-09-26 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-09-27 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-09-28 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-09-29 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-09-30 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-10-01 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-10-02 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-10-03 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-10-04 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-10-05 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-10-06 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-10-07 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-10-08 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-10-09 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-10-10 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-10-11 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-10-12 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-10-13 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-10-14 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-10-15 | $1.25 | $15,968,639,694 | 8 / 10 |
| 2026-10-16 | $1.25 | $15,969,278,714 | 8 / 10 |
| 2026-10-17 | $1.25 | $15,969,278,714 | 8 / 10 |
| 2026-10-18 | $1.25 | $15,969,278,714 | 8 / 10 |
| 2026-10-19 | $1.25 | $15,969,278,714 | 8 / 10 |
| 2026-10-20 | $1.25 | $15,969,278,714 | 8 / 10 |
| 2026-10-21 | $1.25 | $15,969,278,714 | 8 / 10 |
| 2026-10-22 | $1.25 | $15,969,278,714 | 8 / 10 |
| 2026-10-23 | $1.25 | $15,969,278,714 | 8 / 10 |
| 2026-10-24 | $1.25 | $15,969,278,714 | 8 / 10 |
| 2026-10-25 | $1.25 | $15,969,278,714 | 8 / 10 |
| 2026-10-26 | $1.25 | $15,969,278,714 | 8 / 10 |
| 2026-10-27 | $1.25 | $15,969,278,714 | 8 / 10 |
| 2026-10-28 | $1.25 | $15,969,278,714 | 8 / 10 |
| 2026-10-29 | $1.25 | $15,969,278,714 | 8 / 10 |
| 2026-10-30 | $1.24 | $15,969,319,889 | 8 / 10 |
| 2026-10-31 | $1.24 | $15,974,189,053 | 8 / 10 |
| 2026-11-01 | $1.24 | $15,974,189,053 | 8 / 10 |
| 2026-11-02 | $1.24 | $15,981,711,480 | 8 / 10 |
| 2026-11-03 | $1.24 | $15,981,711,480 | 7 / 9 |
| 2026-11-04 | $1.24 | $15,981,711,480 | 7 / 9 |
| 2026-11-05 | $1.24 | $15,981,711,480 | 7 / 9 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 12 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 1 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings5 of 5 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.